Dipeptidyl Peptidase-4: A Potential Therapeutic Target in Diabetic Kidney Disease with SARS-CoV-2 Infection | Zendy

Chhanda Charan Danta | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Dipeptidyl Peptidase-4: A Potential Therapeutic Target in Diabetic Kidney Disease with SARS-CoV-2 Infection

Author(s) -

Chhanda Charan Danta

Publication year - 2020

Publication title -

acs pharmacology and translational science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.271

H-Index - 10

ISSN - 2575-9108

DOI - 10.1021/acsptsci.0c00097

Subject(s) - dipeptidyl peptidase 4 , medicine , dipeptidyl peptidase , kidney , immune system , disease , coronavirus , receptor , respiratory tract , respiratory system , covid-19 , diabetes mellitus , immunology , pharmacology , enzyme , infectious disease (medical specialty) , biology , endocrinology , type 2 diabetes , biochemistry

Dipeptidyl peptidase-4 (DPP-4) is expressed ubiquitously in many tissues, including kidney, respiratory tract, and immune cells. Human DPP-4 has been identified as a functional receptor for the spike glycoprotein of the Middle East respiratory syndrome coronavirus. A large interface has been predicted in the docking of DPP-4/SARS-CoV-2 spike protein. Globally, 40% of diabetic patients develop diabetic kidney disease (DKD), a leading cause of end-stage renal disease. DPP-4 inhibitors possess anti-inflammatory properties which suggest their potential implication in DKD and SARS-CoV-2 immunopathogenesis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research